COMBINED BRACHYTHERAPY AND HYPERTHERMIA

这项提议的目的是回答这个问题，“是结合的 低剂量率近距离放射治疗和热疗优于低剂量 如果是这样的话，最好的方法是什么？ 把热疗和近距离放射治疗结合起来？ 由于热辐射和低剂量率联合辐射的细胞培养研究-- 辐射已经产生了重要的放射生物学线索，体内肿瘤和 需要进行正常的组织研究来解决一些具体问题 与临床应用相关。 有四个具体目标来实现 学习。它们是：(1)可产生的最佳辐射剂量率 最大热辐射增敏，(Ii)最佳温度和 热处理的持续时间，(三)加热的顺序和时间 辐射，以及(Iv)关键正常组织的影响 热量和辐射的结合。我们计划使用两种肿瘤系统：RIF C3H小鼠和9L小鼠肌肉内生长的纤维肉瘤 Fischer大鼠脑内生长的胶质肉瘤。ANA的终点- 肿瘤的溶解包括：(I)克隆形成试验，(Ii)肿瘤生长 延迟，以及(Iii)肿瘤治愈率。正常组织的终点 包括半定量皮肤评分和组织病理学改变 纸巾。基于上述终点，量化估计 计算热增强率和治疗增益。 这项研究的意义将是双重的：确定 可能提高卵巢癌治疗率的放射生物学因素 热疗与低剂量率放射治疗的联合应用 对治疗抗辐射人类肿瘤的研究结果包括 脑部恶性胶质瘤和软组织肉瘤。

The objective of this proposal is to answer the question, "Is combined use of low dose rate brachytherapy and hyperthermia superior to low dose rate brachytherapy alone?". If so, what would be the optimum means to combine heat and brachytherapy? Since cell culture studies of the combined heat and low dose rate irra- diation have yielded important radiobiological clues, in vivo tumor and normal tissue studies are needed to address a number of specific issues relevant to clinical applications. There are four specific aims to achieve the overall objective of the study. They are: (i) an optimum radiation dose rate that would yield the maximum heat radiosensitization, (ii) an optimum temperature and duration of heat treatment, (iii) sequence and timing of heat and radiation, and (iv) the effects of critical normal tissues from the combined heat and radiation. We plan to use two tumor systems: RIF fibrosarcoma growing in the intramuscular site of C3H mice and 9L gliosarcoma growing in the brain of Fischer rats. The end points of ana- lysis for tumors include: (i) clonogenic assays, (ii) tumor growth delays, and (iii) tumor cure rates. The end points for normal tissues include semiquantitative skin scorings and histopathological changes of the tissues. Based on the foregoing end points, a quantitative estimate of thermal enhancement ratio and therapeutic gain will be made. The significance of the study would be two-fold: identification of radiobiological factors that might improve the therapeutic ratio of the combined hyperthermia and low dose rate radiotherapy, and application of the findings to the treatment of radioresistant human tumors, including malignant gliomas of the brain and soft tissue sarcomas.